BioSpace News Archive

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United States Patent Application titled, “Nanoparticles and Template Directed RIG-I Agonist Precursor Compositions and Uses Thereof For Cancer Therapy“ (Pub. No.: US 2024/0042070 A1; Pub. Date: February 8, 2024).

Tonix Pharmaceuticals Holding Corp. today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 26, 2024 at 1:30 p.m. ET in New York City.

SkinCure Oncology announced the publication of research, “Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer,” in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology.

Organon (NYSE: OGN), a global healthcare company with a dedicated commitment to biosimilars, announced that the US Department of Veterans Affairs (VA) has exclusively selected HADLIMA in replacement of HUMIRA (adalimumab) for the VA National Formulary.

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in March.

National Resilience, Inc. today announced the expansion of the company’s clinical and commercial drug product manufacturing capabilities across its network.

Fractyl Health, Inc. today announced the appointment of Samuel Conaway to its Board of Directors.

AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie’s current president and chief operating officer, to succeed Richard A. Gonzalez.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Orphan Drug Designation (ODD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (PV).

BostonGene announced today that it will participate in the 21st Japanese Society of Medical Oncology (JSMO) Annual Meeting.